Palabras clave Salmonella enteritidis. Mionecrosis. Fascia. Código numérico 16 Salmonella enteritidis es un microorganismo que raramente afecta al componente muscular. Recogemos el caso de un paciente varón con Síndrome de Inmunodeficiencia Adquirida (SIDA), que tras un episodio de gastroenteritis aguda debida a Salmonella enteritidis presenta, varios meses después, una necrosis muscular masiva en los miembros inferiores, que le llevó al shock séptico y posteriormente a la muerte.

No abstract

Backgroundin March 2012 was implemented a FLS Unit coordinated by RheumatologyObjectivescommunicate the results of the unit in the 2012–2017 period.MethodsPatients>50 years with fragility fracture. The program consists of: 1) training of primary care doctors (GP), 2) recruitment from the emergency room or admitted with hip fracture; 3) Bone densitometry; 4) patient education by a nurse; 6) report to GP with recommendations of managing; and 7) follow-up of persistence of treatment (telephonic survey plus prescription in the electronic records) at 3, 6, 12 and 24 months.ResultsThe FLS has attended 1739 patients: mean age 73 y, 81% women. The location of fractures was forearm (32%), hip (24%), humerus (21%), vertebra (10%) and other locations (12%). Previous treatment with bisphosphonate 17%, 10% of them at baseline.After the baseline visit, 75% of patients were sent to GP and 25% to rheumatology. Treatment with bisphosphonate or equivalent was recommended to 1264 patients (72%). Persistence of treatment (analysed at 3, 6, 12 and 24 months in 1,051, 823, 622 and 351 patients, respectively) was 74%, 72%, 75% and 69%, respectively.Risk factors (FRAX), n (%) Previous fracture323 (18) Parent’s hip fracture190 (11) Glucocorticoids148 (8) Somking186 (10) Alcohol68 (4) Secondary Osteoporosis287 (16) BMI<18.531 (2) Rheumatoid arthritis40 (2)Bone Densitometry, n (%) Normal159 (13) Osteopenia551 (45) Osteoporosis517 (42)FRAX, mean (DE) Major Fracture13,2 (9) Hip Fracture6 (7)ConclusionsOur FLS is effective in terms of beginning and persistence of antifracture treatment in the medium term.Disclosure of InterestNone declared